On 26 June, AB Science reported interim analysis results for their Phase III trial of masitinib, a drug that is classed as a tyrosine kinase inhibitor. Masitinib is thought to act by inhibiting tyrosine kinases that promote neuroinflammation, amyloid beta signalling and Tau phosphorylation. Following on from a successful Phase II clinical trial of masitinib in 2011, AB Science completed Phase III trial recruitment in mid-2018. This trial (AB09004) was an international, randomised, placebo-controlled study that evaluated the efficacy and safety of masitinib as an add-on therapy to cholinesterase inhibitors and/or memantine. 720 patients with confirmed mild to moderate AD were enrolled and randomised to placebo or one of two doses of masitinib. AB Science reported that their pre-planned interim analysis of the study data had detected a positive trend of efficacy in one of the masitinib doses tested. Final analysis will be completed by the end of 2019.
AB Science reports interim analysis for Phase III trial of masitinib for mild to moderate AD
26/06/2019
